PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,341,408
|
protect role caffeic acid bovin mammari epitheli cell inhibit growth biofilm format gram negat bacteria isol clinic mastiti milk first line barrier bacteri infect mammari tissu bovin mammari epitheli cell bmec general believ involv immun respons due exogen stress due escal crisi antibiot resist urgent need new strategi combat pathogen bacteria infect bovin mastiti studi isol bmec institut cancer research icr mice use escherichia coli infect caffeic acid ca pretreat experi vitro vivo inhibitori effect ca bacteri growth biofilm format also demonstr bacteria strain isol mastiti infect milk demonstr ca supplement prohibit growth predomin strain bacteria isol clinic bovin mastiti milk sampl ca found disrupt biofilm format e coli b sub minimum inhibitori concentr sub mic inhibit adher properti e coli bmec decreas stain bacteria cell surfac vitro addit ca found attenu proinflammatori oxid respons cell infect e coli pretreat bmec ca also restor alter lipid homeostasi caus e coli stimul protect role ca confirm via administr ca mice follow repres gram negat bacteri infect collect find highlight potenti ca mediat gram negat infect indic potenti develop novel antibacteri drug
|
D008892;D008414
|
T168;T047;T031
|
36,341,407
|
strongyloidiasi stercorali coinfect associ alter iron status biomark tubercul lymphaden soil transmit helminth main strongyloidiasi stercorali ss tubercul lymphaden tbl coinfect human signific public health problem previous shown tblss coinfect signific alter divers cytokin matrix metalloproteinas tissu inhibitor metalloproteinas profil howev data avail understand influenc ss coinfect tbl diseas respect iron status biomark henc studi effect ss coinfect circul level iron status ferritin transferrin tf apotransferrin apot hepcidin hemopexin biomark tbl diseas result show tblss andor tblss individu associ signific alter biochem hematolog red blood cell rbc count hemoglobin hb hematocrit hct mean corpuscular volum mcv mean corpuscular hemoglobin mch decreas platelet increas paramet compar tbl ss individu result also show tblss coinfect associ diminish circul level ferritin apot hepcidin hemopexin compar tblss individu tblss tblss group associ alter iron status biomark decreas ferritin tblss alon increas tf apot hepcidin hemopexin tblss alon compar tbl ss group heat map express profil princip compon analysi pca analysi iron status biomark signific alter tblss compar tblss andor tbl ss individu signific correl positiveneg obtain among biochem hematolog paramet white blood cell wbc ferritin tf hepcidin mean corpuscular hemoglobin concentr mchc ferritin hemopexin iron status biomark final receiv oper characterist roc analysi reveal hemopexin signific associ greater specif sensit discrimin tblss tblss coinfect individu thus data conclud ss coinfect associ alter iron status biomark indic coinfect might alter host mtb interfac could influenc diseas pathogenesi
|
D013322;D060085;D014388
|
T047
|
36,341,406
|
gut associ lymphoid tissu galt primari cell stabl cell line predict model intestin health rainbow trout oncorhynchus mykiss use function feed farm fish regard key factor improv fish health perform infecti diseas howev mechan nutrit compon modul immun respons fulli understood present studi undertaken identifi suitabl primari gut associ lymphoid tissu galt leucocyt cell establish rainbow trout cell line potenti altern method test function feed ingredi prior full fish feed trial take month complet addit primari galt cultur cell two rainbow cell line rts rtgutgc macrophag gut epitheli cell respect cell stimul varieti pathogen associ molecular pattern pamp pha poli c recombin rainbow trout il ril proinflammatori cytokin addit two form glucan prebiot common use aquafe use stimul suitabl cell model health screen function feed assess galt leucocyt deem effect act health screen hr time point demonstr respons poli c pha ril rts rtgutgc also respond stimul give strong cell respons like reflect natur cell type oppos mix cell popul primari galt cell cultur stimul form glucan galt leucocyt demonstr strong proinflammatori cell respons
|
D017686;D047071
|
T121;T109;T013
|
36,341,405
|
metagenom wide associ studi gut microbiota recurr aphthous ulcer regul thalidomid recurr aphthous ulcer rau one common diseas human unknown etiolog difficult treat thalidomid import immunomodulatori antitumor drug effect gut microbiota still remain unclear conduct metagenom sequenc studi fecal sampl cohort individu rau perform biochem assay cytokin immunoglobulin antimicrobi peptid serum saliva investig regul effect thalidomid administr withdraw meanwhil construct correspond predict model metagenom wide associ result indic gut dysbacteriosi microbi dysfunct immun imbal occur rau patient thalidomid regul gut dysbacteriosi speci specif manner differ sustain effect various probiot pathogen previous unknown associ gut microbiota alter rau found specif role thalidomid modul gut microbiota immun determin suggest rau may affect target gut dysbacteriosi modifi immun imbal depth insight sophist network consist gut microbiota host cell may lead develop emerg treatment includ prebiot probiot synbiot postbiot
|
D000069196;D013281
|
T047;T007;T001
|
36,341,404
|
explor share featur b cell receptor cell receptor repertoir reveal distinct clonotyp cluster although b cell cell integr player adapt immun system act co depend way orchestr immun respons exist method studi immun repertoir larg focus separ analys b cell receptor bcr cell receptor tcr repertoir base hypothesi share histori immun exposur share cellular machineri recombin result similar bcr tcr repertoir individu examin common interrelationship bcr tcr repertoir find bcr tcr repertoir covari clonal architectur divers pattern correl appear alter immun mediat diseas furthermor hierarch cluster public b cell clonotyp health diseas base correl clonal proport reveal distinct cluster b cell clonotyp exhibit increas sequenc similar share motif distinct amino acid characterist find point common principl govern memori format recombin clonal expans antigen b cell within individu signific proport public bcr tcr repertoir cluster nonoverlap correl cluster suggest novel way group b cell clonotyp
|
D011948;D011947
|
T129;T116;T192
|
36,341,403
|
dietari phytat prime epitheli antibacteri immun intestin although diet long associ suscept infect dietari compon regul host defens remain poor understood demonstr consum rice bran decreas suscept intestin infect citrobact rodentium murin pathogen similar enteropathogen e coli infect human rice bran natur contain high level substanc phytat interest phytat supplement also protect intestin infect enzymat metabol phytat commens bacteria necessari phytat induc host defens mechanist phytat consumpt induc mammalian intestin epitheli express stat regul antimicrobi pathway increas phosphoryl stat suggest dietari phytat promot innat defens epitheli stat activ phytat regul epitheli stat mediat microbiota sensit enzym histon deacetylas hdac collect data demonstr metabol dietari phytat microbiota decreas intestin infect suggest consum bran phytat enrich food may repres effect dietari strategi prime host immun
|
D010833;D004756
|
T121;T127;T109;T047;T130
|
36,341,402
|
impair intratumor natur killer cell function head neck carcinoma natur killer nk cell emerg uniqu player immun respons cancer howev limit data avail tumor infiltr nk cell head neck squamous cell carcinoma hnscc one common cancer occurr hnscc close relat immun microenviron immunotherapi increas appli set howev limit success type treatment tumor call investig field surgic hnssc specimen consecut patient mechan enzymat dissoci tumor cell separ infiltr cell short centrifug infiltr nk cell phenotyp function character multipl antibodi stain flow cytometri tumor infiltr nk cell hnscc show peculiar phenotyp predomin character increas nkga reduc siglec nkgd nkp cd express phenotyp associ decreas abil perform antibodi depend cellular cytotox adcc howev nk cd cd share increment glucocorticoid induc tumor necrosi factor relat gitr costimulatori receptor could exploit immunotherapi agonist anti gitr antibodi combin checkpoint inhibitor
|
D006258
|
T191
|
36,341,401
|
case report sever combin immunodefici ligas defici omenn like manifest dna ligas defici extrem rare primari immunodefici patient report literatur common manifest includ radiosensit macrocyt anemia lymphopenia increas percentag gamma delta cell hypogammaglobulinemia requir replac therapi two month old girl delay develop b nk scid macrocyt anemia present featur omenn syndrom whole exom sequenc reveal two novel heterozyg variant c g gt pargg cg gt ppro lig gene nm hematopoiet stem cell transplant fulli match unrel donor perform age month use gefa protocol mix donor recipi chimer observ chimer mononucl cell compart lymphocyt compart autolog myeloid recoveri stabl cd cd cell count l achiev month patient remain transfus depend despit satisfactori immunolog reconstitut second transplant due constitut hemolyt defect consid light possibl transplant issu optim condit protocol suffici myeloid engraft import first time omenn syndrom describ compound heterozygot carri two novel variant pargg ppro lig gene patient diagnos scid omenn syndrom show macrocyt anemia screen dna ligas defici
|
D016511;D018380;D000748
|
T061;T047
|
36,341,400
|
differ inflammatori marker profil cognit function deficit nondeficit schizophrenia deficit schizophrenia ds patient homogen subtyp schizophrenia includ primari endur negat symptom studi aim compar differ cognit function plasma level c reactiv protein crp inflammatori cytokin among ds patient nondeficit schizophrenia nds patient healthi control hcs total schizophrenia patient hcs includ studi schizophrenia patient divid ds n nds n group base proxi deficit syndrom scale pds posit negat syndrom scale panss repeat batteri assess neuropsycholog status rban use evalu clinic symptom cognit perform respect plasma level crp il il il il il il il il tnf ifn measur use enzym link immunosorb assay elisa result show ds patient worst cognit perform especi immedi memori attent languag dimens compar nds hc group compar hcs group ds patient higher level crp il il il ifn total proinflammatori cytokin nds patient higher level il ifn proinflammatori cytokin also found crp level signific increas ds patient compar nds patient moreov stepwis logist regress analysi reveal crp independ risk factor ds sex stratif analysi show signific differ almost cytokin femal sampl male sampl signific differ cognit perform inflammatori compon among group suggest deficit syndrom independ endophenotyp schizophrenia patient uniqu immun inflammatori featur may sex characterist
|
D012559
|
T048
|
36,341,399
|
immun factor complex causal regul effect bone miner densiti recent evid gradual recogn immun skelet system two close correl system specif immun factor bone miner densiti bmd larg unknown base summari level data genom wide associ studi gwass perform seri analys includ two sampl mendelian random mr analysi test potenti causal link immun trait includ median fluoresc intens mfis absolut cell ac count relat cell rc count morpholog paramet mp bmd fals discoveri rate fdr correct mfi bmd ac bmd rc bmd mp bmd pair reach level signific fdr adjust p lt mfi trait b cell panel largest number signific immun trait pair panel cd molecul express four subset monocyt highlight due consist posit correl bmd four site ac rc trait immun trait cell panel also highlight cd posit cell subset frequent observ featur mp trait signific associ immun trait bmd ssc cd monocyt sensit analys suggest identifi immun factor robust pleiotropi multivari mr analysi confirm independ causal effect sever immun trait bmd mediat analys show cd monocyt could mediat multipl immun trait especi suggest associ cd sever memori b cell bmd mediat cd cd cd monocyt studi repres first comprehens evalu causal effect immun trait risk osteoporosi find highlight complex import role immun deriv factor pathogenesi osteoporosi
|
D015519;D010024
|
T201;T081;T047
|
36,341,398
|
integr metabolom lipidom studi patient atop dermat respons dupilumab atop dermat ad one common chronic inflammatori skin diseas dupilumab monoclon antibodi target interleukin il il receptor wide use ad efficaci howev metabol chang occur patient ad respons dupilumab remain unknown studi integr metabolom lipidom analys clinic data explor potenti metabol alter associ dupilumab therapeut efficaci addit investig whether develop treatment side effect link dysregul metabol pathway
|
D003876
|
T047
|
36,341,397
|
downregul vitamin receptor express acut gastrointestin graft versus host diseas associ poor outcom allogen stem cell transplant vitamin receptor vdr critic regul intestin homeostasi emerg evid demonstr vdr defici critic factor inflammatori bowel diseas patholog howev clinic data exist regard intestin express vdr patient allogen haematopoiet stem cell transplant hsct analyz intestin biopsi patient undergo hsct mortal follow demonstr patient sever acut gastrointestin graft versus host diseas gi gvhd show signific downregul vdr gene express compar mild acut gi gvhd patient p reduc vdr express alreadi detect acut gi gvhd onset compar gvhd free patient p result confirm immunohistochemistri ihc patient sever acut gi gvhd show fewer vdr cell p reduc vdr stain score p compar mild acut gi gvhd patient accord low vdr gene express associ higher cumul incid treatment relat mortal trm p x relaps relat mortal rrm multivari cox regress analysi identifi low vdr independ risk factor trm p hazard ratio ci furthermor vdr gene express signific correl anti microbi peptid amp gene express defa r p x defa r p conclus find suggest essenti role vdr pathogenesi gut gvhd prognosi patient undergo hsct
|
D006086;D018380
|
T061;T047
|
36,341,396
|
comprehens character tnfsflight implic prognosi immunotherapi human glioma glioblastoma multiform gbm common central neural system malign tumor among adult alongsid microscop spread immunosuppress tumor microenviron also induc refractori make immunotherapi gbm particular import unfortun tradit immun checkpoint inhibitor ici often show limit therapeut effect gbm clinic trial new therapeut strategi target urgent need tnfsflight novel immun checkpoint molecul play essenti role innat acquir immun despit recent advanc understand function tnfsflight varieti cancer type clinic immunolog import tnfsflight human glioma fulli explain employ comprehens silico analysi public avail data analyz molecular immun characterist tnfsflight explor feasibl immunotherapi target total glioma case enrol current studi immunohistochemistri stain base patient tissu n perform valid tnfsflight express higher higher grade glioma mesenchym subtyp sensit prognost marker gbm low grade glioma lgg nomogram prognost model establish base tnfsflight express togeth risk factor addit gene ontolog pathway analysi reveal tnfsflight particip cell activ inflammatori process moreov analysi base structur interact tnfsflight reveal mutat site tumor well crucial interact protein analysi imvigor indic role tnfsflight immunotherapi altogeth result reveal under role tnfsflight immunotherapi target gbm
|
D001932;D005910;D005909
|
T191
|
36,341,395
|
sex differ express pd non small cell lung cancer evid increas indic lung cancer incid femal individu continu rise women higher risk develop adenocarcinoma men male femal individu differ innat adapt immun respons sex differ respons pd pd l depend block immunotherapi whether differenti express pd gender affect respons block treatment current unknown studi examin sex differ serum spd mpd express cell sex hormon level non small cell lung cancer nsclc patient result reveal higher level spd express pd cdt cell femal patient male patient identifi serum spd level express mpd cell signific reduc nsclc also found serum testosteron level increas femal patient compar control subject increas testosteron downregul express mpd cell find provid better understand differ pd express gender nsclc patient effect sex hormon pd express suppli evid earli lung cancer diagnosi respons immun checkpoint inhibitor
|
D002289;D008175
|
T191
|
36,341,394
|
mettl mediat modif enhanc function foxp regulatori cell promot allograft accept n methyladenosin preval form intern mrna modif extens involv treg cell differenti function howev involv function treg cell transplant toler remain elucid use experiment transplant mous model found level treg cell alter induct transplant toler perform dot blot assay subsequ use heterogen treg specif mettl knockout mice foxp mettlf cko reduc mettl express perform islet allograft transplant result reveal reduc express mettl prevent treg cell expans promot infiltr cd cd cell around allograft led rapid allograft reject foxp mettl f cko mice express regulatori cytokin includ il tgf signific decreas foxp mettl f cko mice suppress function treg cell also abrog addit analysi rna seq data reveal soc famili soc soc soc subsequ signal pathway affect mettl mediat modif treg cell modul suppress function transplant taken togeth studi show first time mettl mediat modif essenti suppress function treg cell transplant may serv regulatori element treg cell base therapi transplant medicin
|
D050378;D051858
|
T123;T116;T025
|
36,341,392
|
intraocular human cytomegalovirus ocular diseas distinct viremia capabl escap innat adapt immun exploit hla e mediat peripher central toler human cytomegalovirus hcmv infect develop cmv diseas result various form manifest local organ cmv retin form cmv diseas develop immunocompromis host cmv viremia virus peripher circul enter eye hcmv genom extens diversif ul gene produc peptid sequenc modul nk cell effector function load onto hla e subsequ recogn nkga nkgc receptor notabl hcmv strain carri ul gene encod peptid sequenc ident signal peptid sequenc specif hla hla c allotyp enabl cmv strain escap hla e restrict cdt cell respons variat ul sequenc studi main peripher blood cmv viremia case studi sought investig ocular cmv diseas develop cmv infect cmv gene sequenc compar intraocular fluid peripher blood clinic case ul signal peptid sequenc divers multipl sequenc typic present cmv viremia blood compar intraocular fluid signific stronger nk cell suppress induc ul deriv peptid intraocular hcmv compar identifi peripher blood hcmv present intraocular fluid limit carri ul peptid sequenc correspond leader peptid sequenc host hla class ul deriv peptid hcmv found peripher blood dispar hla class allotyp overal analys cmv retin infer specif hcmv strain ul signal sequenc match host hla signal peptid sequenc cross blood ocular barrier enter intraocular space ul peptid repertoir intraocular fluid ocular cmv diseas regardless host immun status impli virus type like common determin ocular cmv diseas develop thus propos mechan ocular cmv diseas develop particular hcmv type blood exploit peripher central hla e mediat toler mechan thus escap antivirus respons innat adapt immun
|
D003586;D012173
|
T047
|
36,341,391
|
sdf express tumor infiltr lymphocyt identifi clinic subtyp tripl negat breast cancer differ respons neoadjuv chemotherapi surviv studi investig predict prognost valu sdf tripl negat breast cancer tnbc patient underw neoadjuv chemotherapi nac follow standard radic surgeri
|
D020360;D064726
|
T061;T191
|
36,341,390
|
establish valid novel prognost model lower grade glioma base senesc relat gene increas studi indic senesc associ tumorigenesi progress lower grade glioma lgg present less invas natur howev treatment efficaci prognosi predict remain challeng due intrins heterogen therefor establish senesc relat signatur investig prognost role lggs
|
D005910;D001932
|
T191
|
36,341,389
|
fecal lcn level sensit biolog indic gut dysbiosi intestin inflamm multipl sclerosi multipl sclerosi ms report associ intestin inflamm gut dysbiosi elucid under biolog ms link gut inflamm investig gut infiltr immun cell develop spontan experiment autoimmun encephalomyel eae human transgen tg mice express hla dra human cell receptor tcr specif myelin basic protein peptid mbp hla dra complex strike note simultan develop eae coliti suggest link autoimmun diseas central nervous system cns intestin inflamm examin colon mice reveal infiltr mbp specif th cell well recruit neutrophil furthermor observ fecal lipocalin lcn biomark intestin inflamm signific elev predomin produc gut infiltr neutrophil extend find ms patient demonstr fecal lcn level signific elev compar healthi donor hds elev fecal lcn level correl reduc bacteri divers increas level intestin inflamm marker includ neutrophil elastas calprotectin interest bacteria thought benefici inflammatori bowel diseas ibd anaerobutyricum blautia roseburia reduc fecal lcn high ms patient also observ decreas trend serum acet short chain fatti acid level ms lcn high patient compar hds furthermor decreas relat abund blautia massiliensi signific associ reduct acet serum ms patient studi suggest gut infiltr th cell recruit neutrophil associ develop gut dysbiosi intestin inflamm fecal lcn level sensit biolog indic gut dysbiosi multipl sclerosi
|
D009103;D004681
|
T047;T050
|
36,341,388
|
therapeut implic tumor microenviron ovarian cancer patient receiv pd pd l therapi epitheli ovarian cancer eoc rank second common caus gynecolog cancer death convent treatment patient eoc postop therapi along platinum chemotherapi howev effici treatment regimen great need patient diagnos advanc diseas figo stage iii iv whose surviv approxim immunotherapi seem encourag therapeut strategi eoc given crucial role complic interact tumor cell cell tumor microenviron tme influenc respons immunotherapi review discuss feasibl strategi eoc immunotherapi exploit reciproc cancer cell constitu tme
|
D060890;D010051
|
T129;T191;T116
|
36,341,387
|
chimer immun checkpoint protein vaccin inhibit tumorigenesi growth rat cholangiocarcinoma cholangiocarcinoma cca second common primari liver malign carri dismal prognosi due difficulti achiev optim resect poor respons current standard care system therapi previous devis ctla pd l dna cancer vaccin dna vaccin demonstr therapeut effect reduc tumor growth thioacetamid taa induc rat intrahepat cca icca model develop ctla pd l chimer protein vaccin protein vaccin examin effect rat icca model therapeut set icca bear rat receiv either dna plus protein vaccin protein vaccin alon result increas pd l ctla antibodi titer reduc icca tumor burden verifi anim positron emiss tomographi pet scan treat icca bear rat protein vaccin alon led increas ctal antibodi titer correl decreas tumor suv ratio indic regress tumor burden along increas lt gt cd lt gt granzym lt gt gzma lt gt express decreas pd l express tumor cell prevent set dna protein vaccin inject rat induct icca taa protein vaccin induc sustain pd l ctla antibodi titer compar dna vaccin potent prevent icca tumorigenesi correspond protein vaccin dna vaccin downregul pd l gene express hinder carcinogenesi icca taken togeth ctla pd l chimer protein vaccin may function therapeut cancer vaccin prevent cancer vaccin taa induc icca rat model
|
D019496;D018281;D001650
|
T129;T121;T191;T116
|
36,341,385
|
microglia morphophysiolog divers implic cns microglia mononuclear phagocyt mesoderm origin migrat central nervous system cns earli stage embryon develop colon cns prolifer remain abl self renew throughout life maintain number microglia around cell cns parenchyma consid play key role develop homeostasi innat immun cns microglia except divers morpholog characterist activ modifi shape process soma respons differ stimuli broad morpholog spectrum microglia respons consid close correl divers rang function health diseas howev morphophysiolog attribut microglia structur function featur microglia neuron interact remain larg unknown assess current knowledg divers microgli morpholog focus correl microgli shape function also outlin current challeng opportun futur direct help us tackl unansw question microglia continu unravel mysteri microglia shape
|
D017628;D002490
|
T022;T025
|
36,341,384
|
autoantibodi enemi andor potenti alli autoantibodi well known potenti high harm antibodi attack host via bind self antigen thus caus sever associ diseas symptom eg autoimmun diseas howev detect autoantibodi rang diseas associ antigen enabl success usag import tool diseas diagnosi prognosi treatment sever advantag use autoantibodi includ capac measur presenc earli diseas develop stabil often much better relat antigen capac use array autoantibodi enhanc diagnost better predict prognosi may also possess capac util therapi vivo review posit negat aspect autoantibodi critic assess includ role autoimmun diseas cancer global pandem caus covid import issu relat detect also highlight
|
D000086382;D001327
|
T047;T067
|
36,341,382
|
alter gut microbiota patient immunoglobulin light chain amyloidosi emerg evid reveal gut microbi dysbiosi implic develop plasma cell dyscrasia amyloid deposit diseas data avail relationship gut microbiota immunoglobulin light chain al amyloidosi
|
D000069196;D000075363
|
T007;T191;T001
|
36,341,381
|
innat lymphoid cell type cancer cancer multifactori chronic ill caus combin genet environment factor tumor collect cancer cell also contain infiltr resid host cell constant interact innat lymphoid cell ilc recent found within tumor microenviron close relationship cancer cell although ilc lack antigen specif receptor respond environment stress signal aid fast orchestr earli immun respons tissu resid cell most locat mucosa first barrier organ main studi defens pathogen lymphoid develop tissu repair howev current research begun elucid involv carcinogenesi nevertheless among ilc ilc found controversi term tumor immun found enhanc anti tumor immun detect cancer cell help lymphocyt infiltr tumor howev recent studi reveal il stimul ilc may promot tumor growth review incorpor recent studi involv ilc cancer develop offer overview role ilc cancer emphasi particular activ sever organ primarili mucosa also breast pancrea liver skin realiz role like depend tissu microenviron subtyp ilc
|
D008214;D009369
|
T191;T025
|
36,341,380
|
harmon qualif intracellular cytokin stain measur influenza specif cd cell immun within flucop consortium despit knowledg cell mediat immun cmi contribut reduct sever influenza infect transmiss diseas outcom correl protect cell mediat immun remain still unclear therefor measur magnitud qualiti influenza specif cell respons harmon way utmost import improv characteris vaccin induc immun across differ clinic trial present studi conduct part flucop project describ develop consensus protocol intracellular cytokin stain ic assay order reduc inter laboratori variabl qualif order develop consensus protocol studi divid differ stage first two pilot studi evalu critic paramet analyt read out post analyt gate strategi data analysi method appli eight differ laboratori within flucop consortium method harmon fix critic paramet subsequ consensus protocol qualifi one flucop member antigen specif cell popul defin polyposit cd cell ie posit least two marker among cdlifniltnf shown sensit specif read qualif consensus protocol show quantif polyposit cd cell precis linear accur sensit lower limit quantif antigen specif polyposit cd cell conclus provid descript harmon ic assay permit quantit qualit evalu influenza vaccin induc cell respons applic harmon assay may allow futur comparison cell respons differ influenza vaccin may facilit futur assess potenti correl protect promis applic across pathogen
|
D007252;D007251
|
T129;T047;T121;T109
|
36,341,379
|
ceacam posit classic monocyt correl interstiti lung diseas earli system sclerosi system sclerosi ssc multipl organ diseas character vascular damag autoimmun tissu fibrosi organ injuri interstiti lung diseas ild result inflammatori fibrosi process lead poor prognosi although autoantibodi detect serum patient ssc mechan immun cell involv tissu inflamm fibrosi fulli understood recent studi reveal carcinoembryon antigen relat cell adhes molecul ceacam posit monocyt involv murin bleomycin induc lung fibrosi investig ceacam posit monocyt patient ssc clarifi role monocyt pathogenesi ssc
|
D017563;D012595;D001172
|
T047
|
36,341,378
|
share biomark pathway system lupus erythematosus metabol syndrom analyz bioinformat combin machin learn algorithm singl cell sequenc analysi system lupus erythematosus sle one preval system autoimmun diseas metabol syndrom met common metabol disord contain hypertens dyslipidemia obes despit clinic evid suggest potenti associ sle met under pathogenesi yet unclear
|
D024821;D008180
|
T047
|
36,341,377
|
tumor microenviron mediat immun toler develop treatment gastric cancer tumor microenviron general term non cancer compon metabolit tumor tissu compon includ extracellular matrix fibroblast immun cell endotheli cell earli stage tumor tumor microenviron tumor suppressor function tumor progress tumor immun toler induc action various factor tumor suppressor microenviron continu transform tumor promot microenviron promot tumor immun escap eventu tumor cell manifest characterist malign prolifer invas metastasi drug resist recent year stress effect extracellular matrix metabol phenotyp chang innat immun cell neutrophil mast cell adapt immun cell tumor microenviron reveal mediat emerg mechan immun toler provid us larg number emerg therapeut target reliev tumor immun toler gastric cancer one common digest tract malign worldwid whose mortal rate remain high accord latest guidelin first line chemotherapi advanc gastric cancer tradit platinum fluorouracil therapi immunotherapi gastric cancer extrem limit includ human epiderm growth factor receptor program death ligand pd l target drug whose benefit limit clinic experi confirm cytotox lymphocyt associ protein ctla vascular endotheli growth factor receptor vegfr target drug alon combin drug limit efficaci patient advanc gastric cancer far less lung cancer colon cancer tumor failur immunotherapi main relat induct immun toler tumor microenviron gastric cancer therefor solv immun toler tumor key success gastric cancer immunotherapi studi summar latest mechan various compon tumor microenviron gastric cancer induc immun toler promot format malign phenotyp gastric cancer well research progress target tumor microenviron overcom immun toler treatment gastric cancer
|
D059016;D013274
|
T070;T191
|
36,341,376
|
alveolar macrophag airway hyperrespons associ respiratori syncyti virus infect respiratori syncyti virus rsv ubiquit pathogen viral bronchiol pneumonia children younger year age close associ recurr wheez airway hyperrespons ahr alveolar macrophag am locat surfac alveoli caviti import innat immun barrier respiratori tract am recogn recruit airspac macrophag recam resid airspac macrophag ram base origin roam trait am polar case rsv infect form two macrophag phenotyp term like like macrophag macrophag macrophag involv modul inflammatori respons among macrophag capabl pro inflammatori respons macrophag capabl anti proinflammatori respons repair damag tissu acut convalesc phase rsv infect polar am affect diseas progress alter immun cell surfac phenotyp well particip regul lymphocyt differenti type inflammatori respons close associ long term ahr recent year progress made regulatori mechan polar caus rsv infect particip acut respiratori inflammatori respons mediat ahr infant summar role rsv infect mediat polar associ ahr infant
|
D018357;D012130;D018113;D011014
|
T047;T046;T050;T005
|
36,341,375
|
mycoplasma bovi adhesin target protein bovin mycoplasmosi import infecti diseas cattl caus mycoplasma bovi bovi pose serious threat breed industri adhesin involv initi process bovi colon close relat infect cell invas immun escap virul pathogen microorgan reason bovi lack cell wall adhesin predomin locat surfac cell membran adhesin bovi usual identifi adhes adhes inhibit analysi adhesin identifi far adhesin primarili bind plasminogen fibronectin heparin amyloid precursor like protein host cell review aim concis summar current knowledg regard adhesin bovi target protein host cell addit biolog characterist adhesin briefli analyz
|
D045682;D009175;D002418
|
T047;T007
|
36,341,374
|
polysaccharid atractylod macrocephala koidz amelior dss induc coliti mice regul thtreg cell balanc atractylod macrocephala koidz one frequent use tradit chines medicin treatment ulcer coliti uc benefici effect polysaccharid atractylod macrocephala koidz pamk uc report under mechan target remain unclear studi systemat investig therapeut effect under mechan pamk uc base mous model dextran sodium sulfat dss induc coliti pamk treatment mgkg mgkg mgkg signific amelior dss induc coliti manifest reduct weight loss diseas activ index dai colon shorten spleen index histolog score moreov pamk treatment inhibit inflamm improv integr intestin barrier coliti mice mechanist microarray analysi determin critic role immunoregulatori effect pamk allevi uc flow cytometri analysi demonstr pamk treatment regul balanc helper th regulatori treg cell mesenter lymph node mln spleen mice coliti addit pamk treatment downregul express il suppress phosphoryl stat togeth data reveal pamk treatment allevi dss induc coliti regul thtreg cell balanc may depend inhibit il stat signal pathway studi first elucid under mechan pamk treatment allevi dss induc coliti associ improv thtreg cell balanc collect studi provid evid potenti pamk treat uc
|
D031174;D003092;D003093
|
T047;T002
|
36,341,373
|
identif valid tyrosin metabol relat prognost predict model character tumor microenviron infiltr hepatocellular carcinoma hepatocellular carcinoma hcc aggress heterogen diseas character high morbid mortal liver vital organ particip tyrosin catabol abnorm tyrosin metabol could caus various diseas includ hcc besid tumor immun microenviron involv carcinogenesi influenc patient clinic outcom howev potenti role tyrosin metabol pattern immun molecular signatur poor understood hcc
|
D006528;D008113
|
T191
|
36,341,372
|
tumor metabol secondari lymphoid organ metabol marker f fludeoxyglucos positron emiss tomographi predict prognosi immun checkpoint inhibitor advanc lung cancer purpos studi investig predict valu tumor metabol paramet combin secondari lymphoid metabol paramet positron emiss tomographi pet comput tomographi ct immun checkpoint inhibitor ici prognosi advanc lung cancer
|
D000072078;D008175
|
T060;T191
|
36,341,371
|
hsp inhibit upregul interferon respons enhanc immun checkpoint blockad therapi murin tumor respons resist immun checkpoint blockad icb immunotherapi remain major clinic challeng may overcom ration combin icb specif target therapeut one emerg combin strategi base sensit icb refractori tumor antagonist kd heat shock protein hsp target four isoform howev pan hsp inhibitor limit modest efficaci target tumor toxic induct heat shock respons hsr overrid effect hsp inhibit recent develop hsp select inhibitor cytotox cancer cell induc hsr vitro report hsp inhibitor ndnb downregul cdk hsp depend client protein induc express endogen retrovir element interferon stimul gene syngen mous model prostat cancer breast cancer ndnb signific augment efficaci icb therapi furthermor ndnb show superior toler pan hsp inhibitor ganetespib mice find provid evid hsp inhibit potenti effect safe regimen combin icb treat immunotherapi refractori solid tumor
|
D000970;D011471
|
T121;T191;T109
|
36,341,370
|
tumor infiltr lymphocyt variabl efficaci treatment solid tumor lymphocyt tumor tissu call tumor infiltr lymphocyt til play key role control treatment tumor diseas sinc discoveri cultur til kill tumor cell time effect cell cultur peripher blood melanoma confirm cultur til success cure clinic patient melanoma sinc investig til isol perform solid tumor modifi procedur increas efficaci thus success establish new til isol cultur method moreov laboratori clinician use cultur til publish paper improv efficaci til carri studi til efficaci treat solid tumor diseas approxim year three main question til studi til remain silent solid tumor tissu til attack homolog heterolog antigen tumor cell solid tumor til infiltr solid tumor tissu distanc tumor site kill tumor cell research three issu increas answer question review summar main issu surround til treat solid tumor review aim studi kill function til solid tumor tissu therebi ultim introduc optim strategi patient suffer solid tumor person immunotherapi near futur
|
D016246;D008545
|
T191;T025
|
36,341,368
|
traumat triad complementopathi endotheliopathi coagulopathi impact clinic outcom sever polytrauma patient complementopathi endotheliopathi coagulopathi follow traumat injuri key pathophysiolog mechan potenti associ multipl organ failur mof mortal howev heterogen respons complementopathi endotheliopathi coagulopathi trauma natur extent interplay relationship clinic outcom remain unclear fifti four poli trauma patient enrol divid three subgroup base iss biomark blood plasma reflect complement activ endotheli damag coagulopathi measur start admiss emerg depart hour admiss compar analys show sever injur patient iss gt associ longer day mechan ventil intens care unit hospit stay higher incid hyperglycemia bacteremia respiratori failur pneumonia compar mild iss lt moder iss injur patient trauma cohort complement activ earli primarili altern complement pathway measur blood plasma sever injur patient signific higher level complement activ product ca ca cb bb endotheli damag marker syndecan stm svegfr hcdna fibrinolyt marker dimer ly compar less sever injur patient sever injur patient also signific lower thrombin generat etp peak lower level coagul factor v viii ix protein c less sever injur patient complement activ correl endotheli damag hypocoagulopathi logist regress analys reveal bb gt gml syndecan gt ngml dimer gt mgl admiss associ higher risk mofmort adjust iss increas triadic score defin bb gt gmlsyndecan gt ngmld dimer gt mgl associ fold higher odd ratio mofdeath p fold greater odd infecti complic p find provid preliminari evid two human injuri respons endotyp traumat triad non traumat triad align clinic trajectori suggest potenti endotyp defin high triadic score patient endotyp may consid time intervent creat pro survivalorgan protect phenotyp improv clinic outcom
|
D001778;D009104
|
T047;T037
|
36,341,366
|
monocyt program cancer therapi monocyt peripher blood circul precursor essenti cell control tumor progress includ tumor associ macrophag tam dendrit cell dcs myeloid deriv suppressor cell mdsc monocyt deriv cell orchestr immun reaction tumor microenviron control diseas outcom effici cancer therapi four major type anti cancer therapi surgeri radiotherapi chemotherapi recent immunotherapi affect tumor associ macrophag tam polar function tam also decreas effici therapi tumor specif way monocyt major sourc tam recruit tumor mass blood circul howev mechan monocyt program circul differ therapeut onset emerg review present state art effect anti cancer therapi monocyt progenitor dedifferenti content monocyt subpopul transcript program circul recruit tumor mass potenti give origin tam tumor specif microenviron also summar limit avail knowledg genet affect monocyt interact cancer therapi highlight perspect therapeut target circul monocyt cancer patient summar knowledg mediat affect monocyt fate four type therapi highlight perspect target monocyt develop combin minim invas anti cancer therapeut approach
|
D009000;D009369
|
T191;T025
|
36,341,365
|
inhibit egfrher amelior neuroinflammatori respons earli stage tau patholog dyrka fda approv egfrher inhibitor varlitinib inhibit tumor growth use cancer treatment howev neuroinflammatori respons associ egfrher under mechan elucid studi evalu impact varlitinib lps tau mediat neuroinflammatori respons first time bv microgli cell varlitinib reduc lps stimul il andor ino mrna level downstream aktfaknf kb signal import varlitinib signific diminish lps mediat microgli nlrp inflammasom activ bv microgli cell primari astrocyt varlitinib downregul lps evok astrogli il mrna level akt signal nlrp inflammasom activ lps treat wild type mice varlitinib signific reduc lps stimul glial activ il nlrp inflammasom format moreov varlitinib signific reduc micro astrogli activ tau hyperphosphoryl month old tau overexpress ps mice downregul tau kinas dyrka level howev month old tau overexpress ps mice varlitinib signific diminish astrogli activ tau phosphoryl thrser taken togeth find suggest varlitinib therapeut potenti lps tau induc neuroinflammatori respons earli stage tau patholog
|
D058847;D000071199
|
T123;T116
|
36,341,364
|
tumor apolipoprotein e key checkpoint block anti tumor immun mous melanoma immunotherapi key modal treatment cancer mani tumor remain immun resist classic mous model b f melanoma immun resist even face checkpoint inhibit apolipoprotein e apo known immun suppress strike elev mani human tumor role cancer immunolog defin investig role apo immun micro environ use mous melanoma model demonstr apo high express wild type b f melanoma serum level progress increas tumor grow condit media wild type apo secret melanoma cell suppress cell activ vitro suppress effect absent condit media apo knock tumor cell mechanist apo induc il secret dendrit cell stimul cell apoptosi arrest partial via lrp receptor ablat apo mice inocul tumor cell enabl tumor cell reject associ induct immun pathway activ immun cell infiltr tumor secret apo appear potent immun cell checkpoint target apo associ enhanc tumor immun mous melanoma model
|
D008546
|
T191;T050
|
36,341,363
|
rna sequenc approach explor therapeut effect umbil cord mesenchym stemstrom cell lipopolysaccharid induc acut lung injuri acut lung injuri ali signific associ morbid mortal patient critic diseas recent year studi identifi mesenchym stemstrom cell mscs amelior ali pulmonari fibrosi howev mechan under outcom ali yet investig studi rna sequenc technolog use analyz gene express profil lung tissu lipopolysaccharid lps induc ali rat follow treatment human umbil cord msc hucmsc differenti express analys gene ontolog annot kyoto encyclopedia gene genom enrich protein protein interact network identif hub gene analysi also perform hucmsc treatment decreas inflammatori factor product alveolar exud attenu lung damag lps induc ali rat rna seq data indic hucmsc treatment activ il jak stat nf b tnf signal pathway increas oxygen transport decreas extracellular matrix organ hucmsc exert benefici effect ali via signal pathway reduc inflamm inhibit pulmonari fibrosi improv lung ventil moreov studi reveal hub gene tbx nkx atf signal pathway involv hucmsc treatment thus provid novel perspect futur research molecular mechan under cell treatment ali hucmsc regul multipl gene signal pathway prevent lps induc lung damag ali rat model
|
D011658;D055371;D059630
|
T047;T025;T037
|
36,341,362
|
integr time seri transcriptom metabolom analys reveal differ inflammatori adapt immun respons contribut host resist prrsv porcin reproduct respiratori syndrom virus prrsv high contagi diseas affect global pig industri understand mechan susceptibilityresist prrsv studi profil time serial white blood cell transcriptom serum metabolom respons prrsv piglet crossbr popul prrsv resist tongcheng pig prrsv suscept larg white pig gene set enrich analysi gsea illustr prrsv infect regul express level marker gene dendrit cell monocyt neutrophil inflammatori respons regul cell b cell nk cell marker cibersort analysi confirm higher cell proport resist pig prrsv infect resist pig show signific higher level cell activ lower express level monocyt surfac signatur post infect suscept pig correspond sever suppress cell immun inflammatori respons suscept pig differenti express gene resistantsuscept pig cours infect signific enrich oxid stress innat immun humor immun cell cycl biotic stimul cellular respons wound respons behavior relat pathway fourteen gene distribut differ qtl region associ prrsv relat trait chemokin cxcl level post prrsv infect differenti express resist pig suscept pig promis marker susceptibilityresist prrsv furthermor metabolom dataset indic differ amino acid pathway lipid metabol pre infectionpost infect resistantsuscept pig major metabolit level also regul prrsv infect signific posit correl express level marker gene adapt immun respons integr transcriptom metabolom reveal concert molecular event trigger infect notabl involv inflammatori respons adapt immun g protein coupl receptor downstream signal studi increas knowledg immun respons differ induc prrsv infect suscept differ transcriptom metabolom level provid basi prrsv resist mechan effect prrs control
|
D019316;D019318
|
T005;T047
|
36,341,361
|
standard vitro evalu car cell use acellular artifici target particl horizon immunotherapi use car cell continu extend treat solid tumor beyond success treatment liquid tumor precis vitro evalu car cell phenotyp quantiti qualiti activ various tumor microenviron includ differ antigen densiti result effector function critic success develop car therapi safe translat clinic unfortun develop method tool accommod need lag behind develop novel biomateri platform acellular artifici target particl aatp car cell use magnet microbead alreadi wide employ manufactur cell product devis simpl standard procedur precis control antigen surfac densiti present aatp wide rang co incub aatp car cell follow flow cytometri cytokin assay quantit determin antigen specif dose depend activ anti car cell also demonstr aatp serv clean target cell vitro assay prove propos mechan action next generat car product overal simpl inexpens modular precis control synthet natur aatp enabl develop clean standard vitro assay car cell provid critic advantag convent assay use target cell line design aatp extend includ tumor antigen relev surfac molecul physiolog target cell thus aatp platform great potenti standard tool develop evalu convent new car product context approv regulatori agenc clinic translat
|
D000076962
|
T129;T116;T192
|
36,341,360
|
liver diseas accompani enteropathi common variabl immunodefici common pathophysiolog mechan common variabl immunodefici cvid one inborn error immun greatest clinic impact rate morbid mortal higher patient cvid develop liver diseas main liver disord cvid nodular regen hyperplasia nrh caus remain unclear yet treatment etiolog liver diseas cvid determin analyz liver injuri associ condit object studi compar cvid patient without liver spleen axi abnorm term clinic characterist well analyz liver duoden biopsi portal hypertens ph elucid pathophysiolog liver injuri patient divid three group liver diseaseph isol splenomegali without liver spleen axi abnorm clinic biochem data collect among cvid patient liver diseaseph isol splenomegali liver spleen axi abnorm among liver diseaseph group patient even mild biochem chang clinic manifest ph main splenomegali thrombocytopenia esophag varic duoden celiac pattern found correl ph p lt identifi nrh liver patient ph n lymphocyt infiltr duoden mucosa also correl ph electron microscopi liver biopsi specimen show vari degre lymphocyt infiltr hepatocyt degener probabl mechan lymphocyt mediat cytotox hepatocyt enterocyt comparison cvid patient without ph ph like lymphadenopathi p lt elev microglobulin p lt low b lymphocyt count p lt low natur killer lymphocyt count p lt cvid patient liver diseaseph common regular imag follow necessari patient distinct immunolog phenotyp may predispos liver duoden injuri lymphocyt mediat cytotox studi could elucid caus immun mediat mechan treatment option
|
D017074;D006975;D007410
|
T047
|
36,341,359
|
transcriptom quantit proteom reveal chang second stimul bone marrow deriv macrophag lupus prone mrllpr mice innat immun memori caus occurr exacerb autoimmun diseas well strong associ pathogenesi system lupus erythematosus sle howev specif mechan remain studi learn ifn stimul generat innat immun memori bone marrow deriv macrophag bmdms activ memori interferon stimul gene isg research use ifn lipopolysaccharid lps treat bmdms lupus prone mrllpr mice show particular memori isg substanti elev prestimul macrophag order identifi differenti express gene deg research turn rna seq go kegg analysi show regul deg enrich defens innat immun respons relat express pattern recognit receptor prrs relat pathway macrophag tmt base proteom analysi reveal differenti express protein dep regul bmdms abund metabol pathway glucos metabol studi found secondari stimul mrllpr mice express prrs innat immun cell chang ifn relat pathway activ releas larg number isg promot secondari respons time relat metabol mode glycolysi enhanc epigenet chang may occur therefor sle brought maintain worsen varieti factor work togeth produc innat immun memori
|
D059467;D008180
|
T081;T047;T086
|
36,341,358
|
pre exist humor immun low pathogen human coronavirus exhibit limit cross reactiv antibodi respons sar cov children sever acut respiratori syndrom coronavirus sar cov infect caus asymptomat mild symptom even rare hospit children major concern whether pre exist antibodi induc low pathogen human coronavirus lph cov children cross react sar cov address unresolv question analyz pre exist spike specif immunoglobin ig g antibodi lph cov cross reactiv antibodi sar cov serum sampl collect children prior sar cov outbreak found seropreval four lph cov reach seroposit sampl cross reactiv igg antibodi nucleocapsid receptor bind domain antigen sar cov addit infect differ lph cov occur frequent children tend increas cross reactiv antibodi sar cov forti nine serum sampl cross reactiv anti igg antibodi sar cov found seven sampl median age year old detect neutral activ wild type mutant sar cov pseudotyp interest seven sampl contain anti igg antibodi hcov oc togeth data suggest children pre exist antibodi lph cov limit cross reactiv neutral antibodi sras cov
|
D000086382;D003332
|
T047;T005;T067
|
36,341,357
|
cd cell associ immun gene panel predict prognosi immunotherapeut effect melanoma skin cutan melanoma skcm frequent encount tumor skin immunotherapi open new horizon melanoma treatment aim construct cd cell associ immun gene prognost model cdigpm skcm unravel immunolog featur benefit immunotherapi cdigpm defin skcm group
|
D008545;D012878
|
T191
|
36,341,356
|
updat interact covid vaccin diabet kidney diseas coronavirus diseas covid still affect worldwid due high infecti natur anrapid spread diabet kidney diseas dkd independ risk factor sever covid outcom certain correl aspect particular activ renin angiotensin aldosteron system chronic inflamm endotheli dysfunct hypercoagul state play import role under mechan link covid dkd dipeptidyl peptidas inhibitor consid potenti therapi covid similar shown organ protect dkd addit neuropilin altern pathway angiotensin convert enzym also contribut sever acut respiratori syndrom coronavirus enter host cell decreas express affect podocyt migrat adhes review pathogenesi current evid interact dkd covid well focus elev blood glucos follow vaccin possibl mechan grasp pathophysiolog dkd patient covid great clinic signific formul therapeut strategi
|
D000086382;D003928;D014612;D003920
|
T129;T121;T116;T067;T047
|
36,341,355
|
synonym mutat pika impact transcript translat process gene express phosphatidylinositol kinas alpha pikiii encod pika gene synthes phosphatidylinositol phosphat pi p serv specif membran marker instrument signal transduct pika mutat caus autosom recess diseas involv neurolog intestin immunolog condit omim detect sepsi sever diarrhea decreas immunoglobulin level one neonat two novel compound heterozyg mutat ct gt c pleupro cc gt pgli identifi neonat father mother respect sanger sequenc revers transcript polymeras chain reaction rt pcr peripher blood minigen splice assay show delet five base gtgag cc gt variant mrna level could result truncat protein pglyglyfst missens mutat ct gt c pleupro kinas activ measur littl catalyt activ detect accord clinic characterist gene mutat function verif pediatrician diagnos child combin immunodefici intestin disord close gastrointestin defect immunodefici syndrom gidid omim medicin immunomodul prescrib balanc immun dysregul studi first report synonym mutat pika gene influenc altern splice find expand mutat spectrum lead pikiiia defici relat diseas provid exact inform genet counsel
|
D000069456;D012326
|
T045
|
36,341,354
|
effect hypoxia antigen present cell base immun recognit hpv transform cell attempt develop therapeut vaccin human papillomavirus hpv induc malign most clinic success date one reason may hypox microenviron present tumor includ cervic cancer hypoxia dysregul level human leukocyt antigen hla class molecul differ tumor entiti impact function cytotox cell lead decreas protein level oncoprotein e e hpv transform cell therefor investig effect hypoxia present hpv e e deriv epitop cervic cancer cell effect epitop specif cell cytotox hypoxia induc downregul e protein level analyz cell line assess western blot howev contrari previous report perturb antigen process present machineri apm compon hla surfac express upon hypoxia treatment detect mass spectrometri flow cytometri respect cytotox assay perform hypox condit show differenti effect specif kill hpv posit cervic cancer cell epitop specif cd cell line donor peptid specif manner effect hypoxia express pd l rule flow cytometri analysi altogeth result hypoxia show decreas express e e intact apm epitop donor depend effect cell cytotox toward hpv posit target cell suggest success immunotherapi develop hypox hpv induc cervic cancer care choic target epitop ideal combin hypoxia allevi measur
|
D002583;D030361
|
T047;T191
|
36,341,353
|
trend industri commerci igi technolog igi technolog refer strateg product process involv generat avian immunoglobulin igi target antigen much cost effect manner broad applic field diagnost prophylaxi therapeut human veterinari medicin past decad promis progress research area evid steep increas number regist manufactur compani involv product igi product number patent notabl number clinic trial underway henc crucial conduct prospect analysi commerci market potenti igi base commerci product larg scale applic review reveal number igi patent applic increas steepli highest patent file addit industri report involv market igi product promot biotherapeut human veterinari medicin diagnost field igi antibodi use primari secondari antibodi approxim product respect biotherapeut product consumpt notabl increas food supplement topic applic human veterinari medicin differ clinic phase develop reach market around product respect contrast number igi product parenter administr licens drug well develop given lack technic standard establish igi registr industri well restrict natur polyclon antibodi howev recent ongo research function igi fragment indic promis area igi applic near futur therefor retrospect analysi specul mandatori igi technolog matur toward industri commerci
|
D004530;D000067896
|
T168;T170;T057
|
36,341,352
|
earli suppress antivir host respons protocadherin sar cov spike protein thp deriv macrophag like cell sever acut respiratori syndrom coronavirus sar cov causat agent coronavirus diseas covid spike protein sar cov play crucial role mediat viral infect henc extens effort curb pandem mani urgent approv vaccin reli express protein aim induc humor cellular respons protect infect given limit inform effect intracellular express protein host cell aim character earli cellular transcriptom chang induc express protein thp deriv macrophag like cell result show wide varieti gene differenti express product main involv cell adhes homeostasi notabl antivir immun respons depict signific downregul protocadherin type alpha interferon ifna initi level ifna higher medium protein express cell downregul observ transcriptom level might reflect increas ifna cytokin beyond h time point compar mock control studi highlight intrins pathogen role protein shed light potenti drawback util context vaccin strategi
|
D000086382;D007370
|
T129;T121;T116;T067;T047
|
36,341,351
|
bibliometr visual analysi neutrophil extracellular trap neutrophil extracellular trap net special structur form neutrophil initi found import kill pathogen bacteria infect develop relat research relationship net diseas sepsi cancer system lupus erythematosus receiv close attent howev lack report comprehens object present current status net relat studi therefor studi aim visual analyz current status trend net relat research mean bibliometr knowledg map
|
D065206;D000086382;D018805;D009369
|
T026;T067;T191;T047;T046
|
36,341,350
|
conform stabil elisa cell base assay reveal patient subgroup target three differ epitop ago antibodi autoantibodi ab biomark mani diseas condit increas use facilit diagnosi treatment decis guarante high sensit specif choic detect method crucial via cell base assay recent found patient neurolog diseas posit antibodi argonaut ago neuropathi np establish simpl conform sensit elisa aim distinguish ago ab conform epitop non conform epitop reveal characterist ago antibodi np autoimmun diseas aid retrospect multicent casecontrol observ studi test patient np diseas control aid healthi control hc ago ab via conform stabil elisa seroposit patient also test conform specif via compar denaturingstabil elisa code elisa cba posit ago titer igg subclass ago reactiv paramet statist compar among differ epitop specif patient group found ab patient includ np aid hc serum reactiv consist higher ago ago global among ago ab posit patient also test cba ago ab posit posit furthermor test conform specif bound conform epitop among subgroup high posit patient elisa z score gt sera bind conform epitop n patient sera also cba posit bound second conform cba inaccess epitop third non conform epitop bound among epitop specif patient subgroup found signific differ regard ab titer igg subclass ago reactiv compar ago ab posit np versus aid patient found conform specif cba inaccess epitop signific frequent aid patient conclud conform elisa sensit cba detect ago ab serum reactiv higher ago ago least np patient ago ab might marker interest np patient distinguish epitop might help find differ patient subgroup
|
D001323;D001327
|
T129;T047;T116
|
36,341,349
|
strategi nlrp inflammasom combat toxoplasma gondii infect protozoan parasit toxoplasma gondii gondii result activ nucleotid bind domain leucin rich repeat contain receptor nlrs turn lead inflammasom assembl subsequ activ caspas secret proinflammatori cytokin pyroptot cell death sever recent studi address role nlrp inflammasom gondii infect without reach consensus role moreov mechan nlrp inflammasom activ differ cell type remain unknown review current research activ specif role nlrp inflammasom gondii infect
|
D014122;D014123
|
T047;T204
|
36,341,348
|
pan cancer analys classic protein tyrosin phosphatas phosphatas target therapi cancer protein tyrosin phosphatas function dephosphoryl target protein regul signal pathway control broad spectrum fundament physiolog patholog process detail knowledg concern role classic ptps human cancer merit depth investig comprehens analyz regulatori mechan clinic relev classic ptps tumor patient across type cancer independ dataset function experi employ valid find exhibit extens dysregul classic ptps construct gene regulatori network human cancer moreov character correl classic ptps drug resist drug sensit respons anti cancer drug evalu ptp activ cancer prognosi generat ptpscore base express hazard ratio classic ptps studi highlight notabl role classic ptps cancer biolog provid novel intellig improv potenti therapeut strategi base ptyr regul
|
D009369;D000970
|
T121;T191;T109
|
36,341,347
|
mir p promot granulosa cell apoptosi ferroptosi nf kb signal pathway polycyst ovari syndrom polycyst ovari syndrom pcos one common endocrin disord women reproduct age mir p report elev granulosa cell pcos patient howev mechan mir p drive granulosa cell gc progress remain unclear thus studi focus role mechan mir p gcs pcos
|
D011085;D035683;D000079403
|
T123;T047;T114;T043
|
36,341,346
|
proteom phosphoryl proteom landscap injur lung juvenil septic rat therapeut applic umbil cord mesenchym stem cell acut lung injuri ali common complic sepsi intraven inject humsc regul level circul endotheli cytokin allevi lung injuri juvenil septic rat studi perform proteom phosphoryl proteom analysi lung tissu juvenil septic rat human umbil cord mesenchym stem cell humsc intervent first time screen potenti protein pathway humsc therapeut effect proteom quantit techniqu use quantit analyz lung tissu septic rat hour biolog sampl hour humsc intervent biolog sampl total protein identifi differenti express protein phosphoryl site chang signific base public databas analyz function enrich protein phosphoryl protein addit tenascin c may key differenti protein ecm receptor interact pathway may main signal pathway use various algorithm analyz protein protein interact network phosphoryl analysi show tight junction pathway close relat immun inflammatori reaction egfr interact may key differenti phosphoryl protein final conserv motif serin phosphoryl site ps conserv motif threonin pt phosphoryl site identifi motif analysi phosphoryl site result proteom phosphoryl proteom potenti new therapeut target humsc allevi lung injuri juvenil septic rat reveal
|
D045164;D059630;D055371;D018805
|
T061;T025;T037;T047;T046
|
36,341,345
|
molecular profil core immun escap gene highlight lck immun relat prognost biomark melanoma tumor microenviron complic continu evolv studi devot identif potenti prognost biomark base tumor microenviron associ immunotherapi melanoma studi integr coupl melanoma singl cell transcriptom sequenc dataset perform seri silico analys nice valid molecular biolog techniqu core set immun escap relat gene identifi lawson et al immport portal differenti protein identifi cbioport databas regress analysi use profil independ prognost factor correl level immun cell infiltr evalu multipl algorithm capac lck predict respons assess two independ immunotherapi cohort high lck express associ better prognosi high level til better clinic stage pathway analysi show high express lck signific associ activ multipl tumor pathway well immun relat pathway lck express tend higher immunotherapi respons patient lower ic treat chemotherapeut agent rt qpcr detect lck express signific upregul melanoma cell line singl cell transcriptom analysi show lck specif high express cell cellchat analysi confirm lck c subpopul cell subpopul exert immun promot cell bind cd receptor conclus lck reliabl biomark melanoma contribut immunotherapi
|
D015972;D008545
|
T045;T191
|
36,341,344
|
ras inhibitor gate chemoattract concentr rang chemotaxi control gpcr mediat adapt cell sensit chemotaxi play essenti role recruit leukocyt site inflamm eukaryot cell sens chemoattract g protein coupl receptor gpcrs chemotax toward gradient enorm concentr rang adapt cell adapt longer respond present stimulus remain sensit stronger stimuli thus adapt provid fundament strategi eukaryot cell chemotax gradient ras activ first step chemosens gpcr signal pathway display transient activ behavior model organ dictyostelium discoideum mammalian neutrophil recent reveal cgap capri control gpcr mediat adapt discoideum human neutrophil respect import ras inhibitor regul sensit cell find suggest evolutionarili conserv molecular mechan eukaryot cell gate concentr rang chemoattract chemotaxi
|
D002633;D004023
|
T204;T038;T043
|
36,341,343
|
immun associ pivot biomark identif compet endogen rna network construct post oper atrial fibril comprehens bioinformat machin learn strategi atrial fibril af common arrhythmia previous studi main focus identifi potenti diagnost biomark treatment strategi af studi concentr post oper af poaf particular use bioinformat analysi machin learn algorithm therefor studi aim identifi immun associ gene provid compet endogen rna cerna network poaf
|
D001281;D035683
|
T123;T047;T046;T114
|
36,341,342
|
spatial transcriptom lacrim gland featur macrophag activ epithelium metabol key alter chronic inflamm lacrim gland lg exocrin gland produc wateri part tear film lubric ocular surfac chronic inflamm sjgren syndrom ss one lead caus aqueous defici dri eye add diseas worldwid studi analyz chronic inflamm lgs nodbsn hbj nodh b mice mous model ss util bulk rnaseq visium spatial gene express seurat perform unsupervis cluster analyz spatial cell distribut gene express chang cell cluster within lg section moreov first time analyz valid specif pathway defin bulk rnaseq use visium technolog determin activ pathway within lg section analysi suggest alter metabol hallmark inflammatori respons epitheli immun cell drive inflamm signific pathway enrich upregul deg tyrobp causal network describ previous ss also note signific decreas lipid metabol lg nodh b mice data suggest modul pathway provid therapeut strategi treat add
|
D007765;D015352;D012859
|
T047;T184;T023;T030
|
36,341,341
|
ibn express b cell dispens igg respons cell depend antigen mice lack atyp inhibitori kappa b ib protein ibn regul nf b pathway encod nfkbid gene display impair antibodi respons cell independ ti cell depend td antigen better understand basi defect cross mice carri flox nfkbid allel mice express cre transcript control cda gene creat mice lack ibn express b cell analys condit knock mice reveal intact cd cd cell popul includ preserv frequenc foxp regulatori cell known reduc ibn knock mice like ibn knock mice mice condit ibn ablat b cell display defect igm respons ti antigen sever reduct periton b cell howev contrast mice lack ibn altogeth condit ibn knock mice respond well td antigen compar control mice potent igg respons follow immun viral antigen rsfv gal wide use hapten protein model antigen np cgg furthermor b cell intrins ibn express dispens germin center gc format follicular helper cell respons np cgg immun result present suggest defect antibodi respons td antigen observ ibn knock mice result b cell extrins defect
|
D001402;D000941
|
T129;T025
|
36,341,340
|
bioengin comput analysi program cell death ligand monoclon antibodi tran membran protein b famili program cell death ligand pd l program death pd play import role inhibit immun respons enhanc self toler via cell modul sever therapeut antibodi use promot cell prolifer prevent interact pd pd l recombin technolog appear quit use product potent antibodi studi construct recombin molecul clone variabl region pd l molecul pmh vector transfer mammalian cell line express g supplement use screen recombin clone maintain serum free medium full length antibodi isol purifi medium supernat concentr mgml antibodi bind affin investig use elisa immunofluoresc method protein protein interact ppi determin use dock approach swiss model util homolog model zdock chimera pymol use valid model ramachandran plot construct use swiss model reveal high qualiti structur valu current technolog allow accur determin antigen antibodi interact
|
D000911;D060890
|
T129;T116
|
36,341,339
|
extracellular vesicl advanc therapeut resolut organ fibrosi current progress futur perspect organ fibrosi serious health challeng worldwid global incid medic burden increas dramat year fibrosi occur near major organ ultim lead organ dysfunct howev current clinic treatment slow revers progress fibrosi end stage organ failur thus advanc anti fibrot therapeut urgent need type natur deriv nanovesicl nativ extracellular vesicl ev multipl cell type eg stem cell immun cell tissu cell shown allevi organ fibrosi mani preclin model multipl effect mechan anti inflamm pro angiogenesi inactiv myofibroblast fibrinolysi ecm compon moreov therapeut potenc nativ ev enhanc multipl engin strategi genet modif precondit therapeut reagent load combin function biomateri review briefli introduc patholog current clinic treatment organ fibrosi discuss ev biolog product strategi particular focus import studi use nativ engin ev intervent attenu tissu fibrosi review provid insight develop translat ev base nanotherapi clinic applic futur
|
D000067128
|
T026
|
36,341,338
|
stereo electron principl select fulli protect chemic synthesis malaria vaccin major histocompat class ii molecul peptid cell receptor mhcii p tcr complex mediat antigen present minim subunit base multi epitop multistag chemic synthesis antimalari vaccin essenti induc appropri immun respons deep understand mhcii p tcr complex stereo electron characterist fundament vaccin develop review encapsul main principl achiev epitop perfect fit mhc ii human hladr aotus aona dr molecul enorm relev sever amino acid physico chemic characterist analys depth data regard distanc farthest atom fit hla dr structur pocket role polyprolin ii like ppiil structur n backbon atom orient establish h bond specif hla dr peptid bind region pbr residu import residu specif charg orient toward tcr induc appropri immun activ amino acid role structur interf ppiil format principl demonstr taken account design immun protect induc peptid structur impip diseas scourg humankind malaria one
|
D017780
|
T129;T121
|
36,341,337
|
human placent hematopoiet stem cell deriv natur killer cell cynk recogn elimin influenza virus infect cell influenza virus iav infect signific recurr threat public health signific burden global economi highlight need develop effect therapi natur killer nk cell play pivot role control pulmonari iav infect howev littl known therapeut potenti adopt transfer nk cell viral infect investig antivir activ cynk human placent hematopoiet stem cell deriv nk cell iav infect vitro virus infect induc express nk cell activ ligand respiratori epitheli cell result enhanc recognit cynk cell upon co cultur iav infect epitheli cell cynk exhibit elev degranul increas product ifn tnf gm csf virus dose depend manner furthermor cynk show virus dose depend cytotox iav infect cell antivir activ cynk mediat nkp nkgd togeth data demonstr cynk possess potent antivir function iav warrant clinic investig adopt nk cell therapi viral infect
|
D009980;D007251
|
T005;T047
|
36,341,336
|
negat regul nlrc potenti role regulatori mechan immun respons immun relat diseas nlrc member pattern recognit receptor nucleotid bind oligomer domain nod like receptor nlrs famili play pivot regulatori role modul activ immun cell macrophag nlrc inhibit activ nf b signal pathway stingtbk signal pathway format inflammasom context cell immun respons nlrc prevent activ cell regul function dendrit cell direct influenc function cell differ pattern recognit receptor nlrc close associ regulatori activ pathogen recognit influenc fate cell exampl prevent prolifer promot apoptosi inhibit pyroptosi cellular function regul nlrc involv develop process varieti diseas infecti diseas steril inflammatori diseas cancer howev characterist function regulatori mechan immun respons immun relat diseas address fulli review elabor potenti role nlrc sever differ level includ molecular mechan cellular function immun relat diseas
|
D036341;D058847
|
T123;T116
|
36,341,335
|
preclin character phase clinic trial ctptsa target met axl vegfr patient advanc solid tumor ctptsa novel tyrosin kinas inhibitor target met axl vegfr flt mertk present preclin data ctptsa conduct first human fih studi evalu use ctptsa adult patient pretreat advanc solid tumor
|
D047428;D009369
|
T121;T191;T116
|
36,341,334
|
advanc immun checkpoint blockad colorect cancer therapi nanotechnolog immun checkpoint blockad icb gain unparallel success treatment colorect cancer crc howev undesir side effect unsatisfactori respons rate tumor metastasi drug resist still hinder applic icb therapi crc advanc icb nanotechnolog game chang develop immuno oncolog nanomateri various nanoplatform fabric enhanc efficaci icb crc treatment herein review systemat summar recent nano strategi accord mechan despit divers complex design nanoplatform four main mechan enhanc icb target immun checkpoint inhibitor ici tumor foci increas tumor immunogen remodel tumor microenviron pre sensit immun system import advantag nanotechnolog crc innov mode action icb modul intestin microbiom integr whole process antigen present highlight review general review describ latest applic nanotechnolog crc immunotherapi may shed light futur design icb platform
|
D000082082;D015179
|
T129;T121;T191;T043
|
36,341,333
|
immunotherapeut progress applic bispecif antibodi cancer bispecif antibodi bsab artifici antibodi two distinct antigen bind site bind differ antigen differ epitop antigen base varieti technolog platform current develop bsab exhibit differ format mechan action upgrad antibodi technolog promot develop bsab effect use treatment tumor far bsab approv market world bsab clinic preclin research stage summar develop process bsab applic tumor treatment look forward challeng futur develop
|
D018033;D009369
|
T129;T121;T191;T116
|
36,341,332
|
rhinovirus induc anti viral interferon secret defici delay sinonas epitheli cell patient chronic rhinosinus nasal polyp dysregul innat adapt immun respons rhinovir infect play import role exacerb progress cours chronic rhinosinus crs howev studi evalu whether rhinovirus induc product anti viral interferon defici delay inflammatori epitheli cell patient crs nasal polyp aim present studi investig replic rate rhinovirus rv rv induc antivir interferon secret express level pattern recognit receptor rv infect tlr stimul poli c normal inflammatori epitheli cell inflammatori epitheli cell obtain crs patient nasal polyp normal epitheli cell deriv ethmoid sinus mucosa endoscop reduct blowout fractur uncin process mucosa patient septal deviat cultur cell infect rv treat poli c h cell media harvest time point use evalu rv replic rate secret ifn viperin mx oa express level trl rig mda phospho nfb phospho irf rv replic rate reach peak level h inocul normal inflammatori epitheli cell show differ group epitheli cell time point releas ifn normal inflammatori epitheli cell also strong induc h rv inocul reach peak level h poli c treatment express level viperin mx oa tlr rig mda phospho nfb phospho irf show similar pattern group epitheli cell result suggest product rv induc antivir interferon defici delay inflammatori epitheli cell crs patient nasal polyp
|
D009298;D012852
|
T047
|
36,341,331
|
petct molecular imag era immun checkpoint inhibitor therapi cancer immunotherapi especi immun checkpoint inhibitor ici pave new way treatment mani type malign particular advanc stage cancer accumul evid suggest molecular imag modal positron emiss tomographycomput tomographi petct play vital role manag ici therapi use differ molecular probe metabol paramet review provid comprehens overview clinic data support import f fluorodeoxyglucos petct f fdg petct imag treatment ici includ evalu tumor microenviron discoveri immun relat advers event evalu therapeut efficaci predict therapeut prognosi also discuss perspect develop direct f fdg petct imag particular emphasi possibl challeng futur addit summar research novel pet molecular probe expect potenti promot precis applic ici
|
D000072078;D009369
|
T060;T191
|
36,341,330
|
compar effect human equival low moder high dose oral prednison intak autoimmun glucocorticoid relat toxic murin model environment trigger lupus autoimmun diseas trigger environment toxic crystallin silica dust csio character dose depend immunomodul toxic glucocorticoid gc prednison preclin model emul onset progress csio trigger lupus two cohort wk old femal nzbwf mice fed either control g diet one three g diet contain prednison mgkg diet span human equival oral dose hed current consid low pl mgd hed moder pm mgd hed high ph mgd hed respect wk age mice intranas instil either salin vehicl mg csio week wk experiment plan termin one cohort mice ngroup wk last csio instil patholog autoimmun assess maintain second cohort ngroup monitor glomerulonephr develop surviv mean blood concentr prednison princip activ metabolit prednisolon mice fed pl pm ph diet ngml respect consist level observ human blood h singl bolus treatment equival prednison dose result first cohort reveal consumpt pm pl diet signific reduc csio induc pulmonari ectop lymphoid structur format nuclear specif aab product inflammationautoimmun gene express lung kidney splenomegali glomerulonephr kidney relat gc associ toxic pm diet pl diet elicit muscl wast diet affect bone densiti caus glucosuria import neither pm pl diet improv latenc csio acceler death ph fed mice cohort display robust gc associ toxic includ bodi weight loss reduc muscl mass extens glucosuria wk final csio instil requir earli remov studi taken togeth result demonstr moder dose prednison reduc import patholog endpoint csio induc autoimmun lupus prone mice upstream ectop lymphoid structur format amelior effect come unwant gc toxic crucial none three dose extend surviv time
|
D005921;D001327
|
T047
|
36,341,328
|
comprehens analysi cuproptosi relat gene tumor microenviron infiltr character breast cancer cuproptosi newli discov program cell death depend overload copper induc mitochondri respir dysregul posit respons immunotherapi one import treatment invas breast cancer depend dynam balanc tumor cell infiltr lymphocyt tumor microenviron tme howev cuproptosi relat gene crgs clinic prognosi immun cell infiltr immunotherapi respons remain unclear breast cancer progress
|
D059016;D001943
|
T070;T191
|
36,341,327
|
low perforin express cd lymphocyt acut phase sever sar cov infect predict long covid cell cytotox play major role antivir immun anti sar cov immun may determin acut diseas sever also potenti persist symptom long covid therefor measur express perforin cytotox mediat cell patient recent hospit sar cov infect recruit volunt confirm sar cov infect rt pcr admit intens care unit icus non icu age sex match healthi control hcs amount intracellular perforin granzym b well cell surfac express degranul marker cda determin flow cytometri level cytokin plasma measur luminex frequenc perforin posit cell cell higher patient hcs versus p vs p respect perforin express neither correl clinic biolog marker diseas sever predict death contrast percentag perforin posit cell acut phase diseas predict onset long covid one year later low cytotox first day sar cov infect might favor virus replic persist autoimmun andor reactiv virus epstein barr virus cytomegalovirus pave way long covid hypothesi boost cell cytotox acut phase infect could prevent delay sequela
|
D000086382;D020031
|
T047;T067
|
36,341,326
|
non heme iron overload impair monocyt macrophag differenti via mitochondri oxid stress iron key element system oxygen deliveri cellular energi metabol thus regul system local iron metabol key maintain energi homeostasi signific chang iron level due malnutrit hemorrhag associ sever diseas hemochromatosi liver cirrhosi copd macrophag key cell regul iron level tissu sequest excess iron iron overload affect macrophag differenti function remain subject debat use vitro model monocyt macrophag differenti studi effect iron overload macrophag function found provid excess iron solubl ferric ammonium citrat fac rather heme iron complex deriv stress red blood cell srbc interfer macrophag differenti phagocytosi impair macrophag differenti coincid increas express oxid stress relat gene addit fac also led increas level cellular mitochondri reactiv oxygen speci ros interf mitochondri function atp generat effect iron overload reproduc mitochondri ros induc rotenon treatment ros scaveng n acetylcystein partial revers fac induc effect final found iron induc oxid stress interf upregul csfr mafb two crucial determin macrophag differenti function summari find suggest high level non heme iron interfer macrophag differenti induc mitochondri oxid stress find might import consid context diseas like chronic obstruct pulmonari diseas copd iron overload defect macrophag function suggest play role diseas pathogenesi
|
D019190;D029424
|
T047
|
36,341,325
|
immunophenotyp pulmonari sarcomatoid carcinoma previous studi suggest patient pulmonari sarcomatoid carcinoma psc may benefit immun checkpoint inhibitor ici howev relev data lack studi aim establish immunophenotyp psc assess pd l cd cell infiltr
|
D008175;D002277
|
T191
|
36,341,324
|
evalu nanobodi base biolog target purinerg checkpoint tumor model vivo adenosin triphosph atp repres danger signal accumul injur tissu inflammatori site tumor microenviron atp promot tumor growth also anti tumor immun respons notabl via px receptor atp also catabol cd cd ecto enzym immunosuppress adenosin px cd cd attract much interest cancer target offer potenti unleash anti tumor immun respons membran protein repres novel purinerg checkpoint target small drug biolog investig nanobodi base biolog target main px also cd alon combin therapi block px inhibit tumor growth improv surviv mice cancer model express px px potenti nanobodi base biolog effect alon control tumor growth enhanc tumor control immun respons use combin oxaliplatin chemotherapi also evalu bi specif nanobodi base biolog target pd l cd novel nanobodi base biolog exert potent anti tumor effect promot tumor reject improv surviv mice two tumor model henc studi highlight import purinerg checkpoint tumor control open new avenu nanobodi base biolog may exploit treatment cancer
|
D059016;D009369
|
T070;T191
|
36,341,323
|
develop improv immunodefici mice human immun system mous model anim model play indispens role studi human diseas howev anim model differ diseas fulli mimic complex intern environ human immunodefici mice defici certain gene express show reduc express cell facilit establish human mice simul human environ vivo summar develop immunodefici mice initi nude mice lack lymphocyt nodscid rgnull mice lack b nk cell popul describ exist human immun system mous model base immunodefici mice human cell tissu transplant establish human immun system includ human peripher blood mononuclear cell hu pbmcs human hematopoiet stem cell hu hscs human bone marrow liver thymus hu blt mous model differ method develop involv vari level complex human human mice wide use studi various diseas provid transit stage clinic research howev sever challeng persist includ improv effici reconstruct human b cell immun respons extend lifespan improv surviv rate mice extend observ period improv develop standard commerci model well use overal mani opportun challeng develop human immun system mous model provid novel strategi understand mechan treatment human diseas
|
D007963
|
T025
|
36,340,967
|
intravitr ranibizumab alon combin calcium dobesil treatment diabet macular edema nonprolif diabet retinopathi patient month outcom retrospect studi studi investig efficaci cad combin intravitr ranibizumab treatment diabet macular edema dme patient nonprolif dr
|
D008269;D003930;D002123;D003920
|
T121;T047;T109
|
36,340,966
|
comparison therapeut effect mini open incis convent open neurolysi median nerv carpal tunnel syndrom aim studi compar therapeut effect mini open incis convent open surgeri carpal tunnel syndrom cts
|
D002349;D000072836
|
T047;T037
|
36,340,965
|
relationship conduct disord prognosi patient acut coronari syndrom conduct disord widen qrs associ poor prognosi patient acut coronari syndrom ac conduct disord includ left bundl branch block lbbb right bundl branch block rbbb nonspecif intraventricular conduct delay nicd previous studi conflict result regard type bundl branch block bbb worst prognosi studi focus prognosi patient nicd
|
D054058
|
T047
|
36,340,964
|
assess manag cognit psychosoci difficulti peopl multipl sclerosi ireland nation survey clinic practic recent survey healthcar profession explor uk healthcar profession typic assess treat multipl sclerosi ms relat cognit impair littl current known constitut usual care cognit impair psychosoci care peopl ms ireland
|
D009103
|
T047
|
36,340,885
|
protocol construct biomimet carbon fiber composit improv interfaci strength weak interfaci strength restrict mechan properti carbon fiber reinforc composit inspir natur hook groov microstructur system hgms black kite milvus migran detail step construct biomimet hgms base dopamin function carbon fiber cfs zinc oxid nanorod zno nrs use two step modif approach describ fabric biomimet carbon fiber composit use vacuum assist contact mold vacm subsequ character use standard comprehens mechan test techniqu complet detail use execut protocol pleas refer wang et al
|
D032701;D015034
|
T090;T197;T121
|
36,340,884
|
protocol ex vivo competit sequenc mycobacterium isol infect guinea pig describ step gdna isol mycobacterium strain isol guinea pig lung detail step infect guinea pig mycobacterium tuberculosi follow vitro growth gdna isol whole genom sequenc also describ ex vivo competit experi determin select advantag one strain anoth includ detail wgs mutat spectrum analysi protocol use identifi mutat aris pathogen bacteria complet detail use execut protocol pleas refer naz et al
|
D009169;D014376
|
T047;T007
|
36,340,883
|
protocol laser induc chronic ocular hypertens intracamer inject nonhuman primat laser induc hypertens nonhuman primat use mimic human glaucoma lead caus irrevers blind protocol detail step laser induc ocular hypertens nonhuman primat laser photocoagul trabecular meshwork subsequ intracamer inject describ record evalu intraocular pressur chang peripapillari retin nerv fiber layer thick protocol assist research improv success rate repeat procedur reduc number nonhuman primat need complet detail use execut protocol pleas refer sun et al
|
D005901;D009798
|
T047
|
36,340,882
|
biosensor cell fit hd correl singl cell fate microscal energi deposit complex ion beam present protocol biosensor cell fit hd enabl long term monitor correl singl cell fate subcellular deposit energi ioniz radiat cell fate track use widefield time laps microscopi uncoupl time confoc ion track imag registr imag acquisit step allow precis ion track assign cell correl cellular readout complet detail use execut protocol pleas refer nikla et al
|
D018499;D015374
|
T075;T059;T067
|
36,340,881
|
protocol carom machin learn tool predict post translat regul metabol signatur protocol describ carom comput tool combin genom scale metabol network gem machin learn identifi enzym target post translat modif ptms condit specif enzym reaction properti use predict target phosphoryl acetyl multipl organ carom influenc accuraci gem associ flux balanc analysi fba generat input model demonstr protocol use multi omic data e coli complet detail use execut protocol pleas refer smith et al
|
D055432;D004926
|
T007;T091
|
36,340,581
|
atf regul osteogen function mediat osteoblast ferroptosi type diabet osteoporosi osteoporosi complic type diabet character reduc bone mass augment bone fragil increas risk fractur thus reduc patient qualiti life especi elder ferroptosi implic patholog process type diabet osteoporosi tdop specif under mechan remain larg unknown studi clarifi role activ transcript factor atf tdop explor specif regulatori mechan provid new treatment target tdop
|
D000079403;D003924;D010024
|
T047;T043
|
36,340,580
|
hsacirc knockdown attenu osteosarcoma progress via regul mir mcam pathway dysregul circular rnas circrna particip malign progress multipl cancer includ osteosarcoma os howev role circ os develop remain unclear thus aim unveil function role mechan circ os
|
D035683;D012516;D001859
|
T123;T191;T114
|
36,340,269
|
transcript factor fxr activ dhrs inhibit cell oxid phosphoryl suppress colon cancer progress colon cancer common gastrointestin malign discov farnesoid x receptor fxr play imper regulatori role multityp cancer recent year howev regulatori mechan colon cancer clear explor studi intend explor molecular regulatori mechan fxr downstream gene malign progress colon cancer
|
D014157;D003110
|
T123;T191;T116
|
36,340,268
|
monocarboxyl transport role regul corneal diabet diabet mellitus dm group metabol diseas known caus structur function ocular complic human cornea dm relat complic affect epithelium stroma nerv monocarboxyl transport mcts famili proton link plasma membran transport carri monocarboxyl across plasma membran context corneal health diseas role presenc function larg undetermin sole focus common mct isoform studi investig regul mct corneal dm use establish self assembl extracellular matrix ecm vitro model primari stromal corneal fibroblast isol healthi hcfs type tdms type ii tdms dm donor monocultur construct creat stimul stromal cell transwel stabl vitamin c two four week cocultur construct creat ad sh syy neuron two differ densiti k k top monocultur data show signific upregul mct week hcf tdm tdm monocultur well k nerv cocultur mct signific upregul hcf tdm monocultur k nerv cocultur mct express week cocultur limit hcfs tdms monocultur immunofluoresc analysi show cytoplasm mct express cell type signific downregul mct mct hcfs compar tdms tdms herein reveal exist modul mcts human diabet cornea vitro chang appear depend neuron densiti suggest mcts like critic neuron defect observ diabet keratopathyneuropathi studi warrant order fulli delin role mcts corneal diabet
|
D003922;D009447
|
T047;T191
|
36,340,218
|
use reduct mammoplasti techniqu oncoplast breast surgeri reconstruct combin reduct mammoplasti techniqu breast reconstruct allow surgeon lift ptotic breast local flap skin reduct surgeri breast cancer studi present reliabl cours combin partial skin nippl spare mastectomi reduct reconstruct surgeri
|
D001943;D016462;D015414
|
T061;T191
|
36,340,185
|
sorafenib entrap self assembl pullulan stearic acid biopolym deriv drug deliveri system plcprf hepatocellular carcinoma model studi aim design prototyp drug deliveri system dds made amphiphil pullulan pull deriv biodegrad polym target asialoglycoprotein receptor asgpr overexpress hcc stearic acid sa conjug increas hydrophob pullulan pull sa
|
D006528;D008113;D053758;D000970
|
T121;T191;T073;T109
|
36,340,183
|
everolimus load reconstitut high densiti lipoprotein prepar novel dual centrifug approach anti atherosclerot therapi convent techniqu prepar reconstitut high densiti lipoprotein rhdl hamper long process time need larg amount start materi harsh prepar condit present novel rhdl prepar method overcom challeng furthermor propos dual mode action rhdl load immunosuppress drug everolimus eve rhdl context atherosclerosi cardiovascular diseas
|
D002318;D050197;D058226
|
T047;T046;T020;T031
|
36,340,009
|
develop intervent moral injuri relat mental health difficulti uk militari veteran feasibl pilot studi protocol background experienc potenti moral injuri event pmi found signific associ poor mental health outcom militari personnelveteran current manualis treatment moral injuri relat mental health difficulti uk veteran exist articl describ design method expect data collect restor amp rebuild r amp r protocol aim develop procedur treat moral injuri relat mental ill health inform codesign approach method studi consist three main stage first systemat review conduct understand best treatment symptom central moral injuri relat mental ill health stage r amp r manual co design support uk veteran particip live experi pmi well key stakehold experi support moral injuri affect individu stage final stage studi conduct pilot studi explor feasibl accept r amp r manual stage result qualit data analys use themat analysi conclus studi approv king colleg london research ethic committe hr find dissemin sever way includ public academ journal free train event present confer provid inform veteran stakehold clinician experi anticip find inform develop accept evid base approach treat moral injuri relat mental health problem may also help inform broader approach provid care trauma expos militari veteran
|
D013313;D014728
|
T098;T048
|
36,340,008
|
development trauma disord distinguish posttraumat stress disord symptom level person centr empir approach development trauma disord dtd propos childhood psychiatr diagnosi psychopatholog development sequela victim attach trauma extend beyond posttraumat stress disord ptsd
|
D013313
|
T048
|
36,340,007
|
trauma relat dissoci autonom nervous system systemat literatur review psychophysiolog correl dissoci experienc ptsd patient background neurophysiolog model link dissoci eg feel detach traumat event hypoarous current assum initi passiv reaction threat may coincid blunt autonom respons constitut dissoci subtyp post traumat stress disord ptsd object within systemat review summar research evalu autonom nervous system activ eg heart rate blood pressur dissoci ptsd patient discern valid current neurophysiolog model trauma relat hypoarous method screen articl studi n subject investig physiolog respons stress provoc trauma relat intervent includ final analysi result clear trend exist across measur physiolog marker trauma relat dissoci extract result inconsist part due high heterogen experiment methodolog conclus current review unabl provid robust evid peri post traumat dissoci associ hypoarous question valid distinct psychophysiolog profil ptsd
|
D013313
|
T048
|
36,340,006
|
mechan govern individu influenc protect behaviour second wave covid multipl mediat model background sar cov virus continu spread resurg global sign second wave despit action govern curb covid pandem howev evid base strategi combat covid recurr poor document object reveal govern individu act effect cope futur wave studi propos prevent model covid resurg method questionnair survey conduct among resid beij epidem reoccur structur equat model use explor mechan among govern intervent perceiv efficaci posit emot posttraumat growth ptg protect behaviour result data analysi reveal covid resurg govern intervent could direct indirect influenc protect behaviour individu factor ie perceiv efficaci posit emot ptg could mediat indirect pathway protect behaviour conclus find impli govern intervent need integr individu factor effect control repeat covid outbreak
|
D000086382
|
T047;T067
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.